marketcaparena
Search

    BIO

    BIO-RAD LABORATORIES, INC.

    Company overview

    Market capitalization
    —
    Employees
    7,450
    Latest publication
    2026-09-29
    About BIO-RAD LABORATORIES, INC.

    Bio-Rad Laboratories, Inc. develops, manufactures, and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, Latin America, and internationally. It operates through two segments, Life Science and Clinical Diagnostics. The Life Science segment develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantify biological materials, including cells, proteins, and nucleic acids used in research and biopharmaceutical laboratory environments, as well as for biopharmaceutical manufacturing, quality control process, food safety, and science education applications. This segment serves universities and medical schools, industrial research organizations, government agencies, pharmaceutical manufacturers, biotechnology companies, food producers, and testing laboratories. Its Clinical Diagnostics segment designs, manufactures, markets, and supports diagnostic test systems, informatics systems, test kits, and specialized quality controls for clinical, hospital, diagnostic reference, and transfusion and physician office laboratories, as well as software. The company offers its products through its direct commercial organization, as well as through distributors, agents, brokers, and resellers. Bio-Rad Laboratories, Inc. was founded in 1952 and is headquartered in Hercules, California.

    Company website

    Financial statements

    Income Quarterly

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricQ2 20262026-06-30 · USDQ1 20262026-03-31 · USDQ4 20252025-12-31 · USDQ3 20252025-09-30 · USDQ2 20252025-06-30 · USDQ1 20252025-03-31 · USDQ4 20242024-12-31 · USDQ3 20242024-09-30 · USD
    Total Revenue651,000,000USD592,100,000USD693,200,000USD653,000,000USD651,600,000USD585,400,000USD667,475,000USD649,729,000USD
    Cost Of Revenue305,200,000USD282,700,000USD348,000,000USD309,600,000USD306,300,000USD279,400,000USD325,563,000USD293,826,000USD
    Gross Profit345,800,000USD309,400,000USD345,200,000USD343,400,000USD345,300,000USD306,000,000USD341,912,000USD355,903,000USD
    Research Development61,200,000USD62,900,000USD65,700,000USD71,300,000USD60,500,000USD73,500,000USD79,624,000USD90,997,000USD
    Selling General Administrative212,000,000USD212,400,000USD221,000,000USD206,800,000USD207,700,000USD208,800,000USD203,958,000USD200,440,000USD
    Total Operating Expenses273,200,000USD275,300,000USD282,300,000USD278,100,000USD268,200,000USD282,300,000USD283,582,000USD291,437,000USD
    Operating Income72,600,000USD34,100,000USD61,900,000USD66,400,000USD77,100,000USD23,700,000USD58,330,000USD64,466,000USD
    Total Other Income Expense Net469,500,000USD-723,900,000USD867,300,000USD-497,500,000USD336,900,000USD59,700,000USD-967,230,000USD797,154,000USD
    Interest Expense12,100,000USD12,300,000USD12,100,000USD12,300,000USD12,600,000USD12,000,000USD12,185,000USD12,174,000USD
    Income Before Tax542,100,000USD-689,800,000USD929,200,000USD-431,100,000USD414,000,000USD83,400,000USD-908,900,000USD861,620,000USD
    Income Tax Expense170,700,000USD-162,700,000USD209,200,000USD-89,200,000USD96,200,000USD19,400,000USD-193,100,000USD208,448,000USD
    Net Income371,400,000USD-527,100,000USD720,000,000USD-341,900,000USD317,800,000USD64,000,000USD-715,800,000USD653,172,000USD
    Interest Income—21,000,000USD31,000,000USD13,700,000USD14,700,000USD36,200,000USD15,900,000USD15,500,000USD
    Net Interest Income—8,700,000USD18,900,000USD1,400,000USD2,100,000USD24,200,000USD3,715,000USD3,326,000USD
    Tax Provision—-162,700,000USD209,200,000USD-89,200,000USD96,200,000USD19,400,000USD-193,115,000USD208,448,000USD
    Net Income From Continuing Ops—-527,100,000USD720,000,000USD-341,900,000USD317,800,000USD64,000,000USD-715,802,000USD653,172,000USD
    Ebit—-677,500,000USD941,300,000USD-418,800,000USD426,600,000USD95,400,000USD-896,700,000USD873,794,000USD
    Ebitda—-636,600,000USD993,700,000USD-364,600,000USD477,200,000USD133,500,000USD-847,400,000USD922,894,000USD
    Depreciation And Amortization—40,900,000USD52,400,000USD54,200,000USD50,600,000USD38,100,000USD49,300,000USD49,100,000USD
    Reconciled Depreciation—40,900,000USD42,500,000USD44,200,000USD40,600,000USD38,100,000USD39,200,000USD38,900,000USD
    Unclassified Operating Expenses——-4,400,000USD—————
    Net Income Applicable To Common Shares——720,000,000USD-341,900,000USD317,800,000USD64,000,000USD-715,802,000USD653,172,000USD
    SourceDisclosureDeterministicFinalLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacy

    Income Yearly

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricFY 20252025-12-31 · USDFY 20242024-12-31 · USDFY 20232023-12-31 · USDFY 20222022-12-31 · USDFY 20212021-12-31 · USDFY 20202020-12-31 · USDFY 20192019-12-31 · USDFY 20182018-12-31 · USD
    Total Revenue2,583,200,000USD2,566,500,000USD2,671,262,000USD2,802,249,000USD2,922,545,000USD2,545,626,000USD2,311,659,000USD2,290,109,000USD
    Cost Of Revenue1,239,600,000USD1,187,600,000USD1,244,316,000USD1,234,919,000USD1,284,449,000USD1,107,739,000USD1,054,663,000USD1,065,747,000USD
    Gross Profit1,343,600,000USD1,378,900,000USD1,426,946,000USD1,567,330,000USD1,638,096,000USD1,437,887,000USD1,256,996,000USD1,224,362,000USD
    Research Development256,899,999USD295,900,000USD247,427,000USD256,889,000USD260,638,000USD217,763,000USD202,710,000USD199,196,000USD
    Selling General Administrative844,300,000USD814,000,000USD846,803,000USD827,825,000USD879,574,000USD800,267,000USD824,625,000USD834,783,000USD
    Unclassified Operating Expenses-23,699,999USD———————
    Total Operating Expenses1,077,500,000USD1,109,900,000USD1,089,100,000USD1,084,714,000USD1,137,760,000USD1,016,561,000USD1,027,335,000USD1,032,490,000USD
    Operating Income270,500,000USD269,000,000USD337,796,000USD482,616,000USD500,336,000USD421,326,000USD229,661,000USD-108,641,000USD
    Interest Income95,500,000USD82,000,000USD96,400,000USD58,000,000USD4,921,944,000USD4,491,393,000USD30,500,000USD26,600,000USD
    Interest Expense49,000,000USD48,900,000USD49,439,000USD38,114,000USD1,551,000USD21,861,000USD23,416,000USD23,962,000USD
    Net Interest Income46,500,000USD33,100,000USD47,639,000USD19,886,000USD-1,551,000USD-21,861,000USD7,084,000USD2,638,000USD
    Income Before Tax995,500,000USD-2,342,500,000USD-850,104,000USD-4,704,273,000USD5,449,055,000USD4,918,007,000USD2,261,081,000USD507,359,000USD
    Income Tax Expense235,600,000USD-498,300,000USD-212,780,000USD-1,076,738,000USD1,194,798,000USD1,103,778,000USD502,406,000USD146,363,000USD
    Tax Provision235,600,000USD-498,300,000USD-27,916,000USD-1,076,738,000USD1,192,247,000USD1,101,371,000USD502,406,000USD147,045,000USD
    Net Income759,900,000USD-1,844,200,000USD-637,324,000USD-3,627,535,000USD4,254,257,000USD3,814,229,000USD1,758,675,000USD360,996,000USD
    Net Income From Continuing Ops759,900,000USD-1,844,200,000USD-159,298,000USD-3,627,535,000USD4,245,902,000USD3,806,267,000USD1,758,675,000USD365,614,000USD
    Ebit1,044,500,000USD-2,293,600,000USD-800,700,000USD-4,666,159,000USD5,450,606,000USD4,939,868,000USD2,284,497,000USD536,621,000USD
    Ebitda1,249,900,000USD-2,142,000,000USD-654,800,000USD-4,488,959,000USD5,588,206,000USD5,078,468,000USD2,458,997,000USD674,721,000USD
    Depreciation And Amortization205,400,000USD151,600,000USD145,900,000USD177,200,000USD137,600,000USD138,600,000USD174,500,000USD138,100,000USD
    Reconciled Depreciation165,400,000USD151,600,000USD144,200,000USD137,300,000USD133,801,000USD138,100,000USD134,200,000USD138,100,000USD
    Total Other Income Expense Net725,000,000USD-2,611,500,000USD-1,187,900,000USD-5,186,889,000USD4,948,719,000USD4,496,681,000USD2,031,420,000USD319,387,000USD
    Net Income Applicable To Common Shares759,900,000USD-1,844,200,000USD-637,324,000USD-3,627,535,000USD4,245,902,000USD3,806,267,000USD1,758,675,000USD365,614,000USD
    Non Operating Income Net Other———44,779,000USD24,022,000USD22,717,000USD23,849,000USD33,732,000USD
    Selling And Marketing Expenses———————1,489,000USD
    SourceLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacy

    Balance sheet Quarterly

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricQ2 20262026-06-30 · USDQ1 20262026-03-31 · USDQ4 20252025-12-31 · USDQ3 20252025-09-30 · USDQ2 20252025-06-30 · USDQ1 20252025-03-31 · USDQ4 20242024-12-31 · USDQ3 20242024-09-30 · USD
    Total Assets10,252,000,000USD9,790,000,000USD10,576,500,000USD9,696,400,000USD10,214,100,000USD9,526,900,000USD9,364,100,000USD10,603,472,000USD
    Cash And Equivalents517,000,000USD—529,800,000USD395,800,000USD369,300,000USD521,400,000USD488,100,000USD410,377,000USD
    Cash And Short Term Investments1,618,500,000USD1,564,700,000USD1,542,700,000USD1,420,600,000USD1,373,800,000USD1,660,400,000USD1,664,500,000USD1,622,458,000USD
    Short Term Investments1,101,500,000USD1,057,500,000USD1,010,900,000USD1,022,800,000USD1,004,500,000USD1,139,000,000USD1,176,400,000USD1,212,081,000USD
    Long Term Investments5,723,600,000USD5,311,800,000USD6,103,600,000USD5,057,800,000USD5,576,500,000USD4,994,200,000USD4,839,200,000USD6,002,635,000USD
    Total Current Assets3,020,500,000USD2,942,100,000USD2,906,200,000USD2,842,000,000USD2,811,100,000USD3,036,600,000USD3,030,300,000USD3,055,620,000USD
    Other Current Assets31,800,000USD180,700,000USD150,300,000USD164,000,000USD168,600,000USD161,400,000USD153,300,000USD166,946,000USD
    Total Liabilities3,078,100,000USD———————
    Total Current Liabilities961,300,000USD917,000,000USD517,000,000USD522,299,999USD548,900,000USD506,600,000USD467,800,000USD497,943,000USD
    Other Current Liabilities158,800,000USD———————
    Other Non Current Liabilities198,500,000USD———————
    Total Stockholder Equity7,173,900,000USD6,851,300,000USD7,453,600,000USD6,736,800,000USD7,128,700,000USD6,679,400,000USD6,569,300,000USD7,487,859,000USD
    Total Equity Including Noncontrolling Interest7,173,900,000USD———————
    Long Term Debt803,000,000USD802,900,000USD1,203,000,000USD1,201,400,000USD1,201,100,000USD1,200,700,000USD1,200,400,000USD1,200,100,000USD
    Deferred Revenue52,500,000USD———————
    Net Receivables441,800,000USD426,200,000USD472,500,000USD474,200,000USD469,900,000USD424,700,000USD452,500,000USD461,940,000USD
    Inventory780,600,000USD770,500,000USD740,700,000USD783,200,000USD798,800,000USD790,100,000USD760,000,000USD804,276,000USD
    Property Plant Equipment Net671,900,000USD689,400,000USD709,900,000USD720,500,000USD740,100,000USD681,700,000USD688,600,000USD719,170,000USD
    Goodwill574,300,000USD———————
    Intangible Assets160,000,000USD166,800,000USD174,300,000USD388,400,000USD396,900,000USD296,100,000USD293,600,000USD307,300,000USD
    Accounts Payable143,500,000USD133,100,000USD129,000,000USD128,800,000USD139,300,000USD137,900,000USD122,300,000USD122,185,000USD
    Short Term Debt33,600,000USD436,700,000USD37,900,000USD38,100,000USD40,600,000USD42,500,000USD42,900,000USD44,096,000USD
    Retained Earnings8,020,600,000USD7,649,200,000USD8,176,300,000USD7,456,300,000USD7,798,200,000USD7,480,400,000USD7,416,400,000USD8,132,231,000USD
    Accumulated Other Comprehensive Income-271,300,000USD-235,400,000USD-189,100,000USD-166,800,000USD-154,100,000USD-409,800,000USD-538,200,000USD-315,274,000USD
    Total Liab—2,938,700,000USD3,122,900,000USD2,959,600,000USD3,085,400,000USD2,847,500,000USD2,794,800,000USD3,115,613,000USD
    Other Current Liab—302,300,000USD313,500,000USD310,599,999USD332,800,000USD289,100,000USD271,400,000USD288,037,000USD
    Capital Stock—0USD0USD0USD0USD0USD0USD3,000USD
    Good Will—577,100,000USD579,800,000USD578,700,000USD581,600,000USD414,600,000USD410,500,000USD415,100,000USD
    Cash—507,200,000USD531,799,999USD397,800,000USD369,300,000USD521,400,000USD488,100,000USD410,377,000USD
    Net Debt—871,000,000USD999,200,000USD997,500,000USD1,037,200,000USD848,100,000USD886,600,000USD977,738,000USD
    Short Long Term Debt—400,500,000USD1,300,000USD1,300,000USD1,300,000USD1,200,000USD1,200,000USD1,262,000USD
    Short Long Term Debt Total—1,378,200,000USD1,531,000,000USD1,395,300,000USD1,406,500,000USD1,369,500,000USD1,374,700,000USD1,388,115,000USD
    Property Plant Equipment Gross—689,400,000USD1,970,900,000USD720,500,000USD740,100,000USD681,700,000USD1,797,800,000USD719,170,000USD
    Common Stock Shares Outstanding—26,958,000shares27,012,000shares26,923,000shares27,228,000shares27,955,000shares27,997,000shares27,985,000shares
    Non Current Assets Total—6,847,900,000USD7,670,300,000USD6,854,400,000USD7,403,000,000USD6,490,300,000USD6,333,800,000USD7,547,827,000USD
    Non Current Liabilities Total—2,021,700,000USD2,605,900,000USD2,437,300,000USD2,536,500,000USD2,340,900,000USD2,327,000,000USD2,617,670,000USD
    Non Current Liabilities Other—198,400,000USD197,800,000USD207,500,000USD209,600,000USD173,100,000USD177,200,000USD197,593,000USD
    Non Currrent Assets Other—102,800,000USD102,300,000USD108,600,000USD107,900,000USD103,700,000USD101,900,000USD103,622,000USD
    Net Working Capital—2,025,100,000USD2,389,200,000USD2,319,700,000USD2,262,200,000USD2,530,000,000USD2,562,500,000USD2,557,677,000USD
    Unclassified Current Liabilities—-355,600,000USD35,300,000USD43,500,000USD34,900,000USD35,900,000USD29,600,000USD42,363,000USD
    Unclassified Non Current Liabilities—1,020,400,000USD1,205,100,000USD1,028,400,000USD1,125,800,000USD967,100,000USD949,400,000USD1,219,977,000USD
    Unclassified Equity—-562,500,000USD-533,603,010USD-552,702,700USD-515,402,600USD-391,202,700USD-308,903,030USD-329,104,000USD
    Common Stock——3,010USD2,700USD2,600USD2,700USD3,030USD3,000USD
    Other Assets——102,700,000USD109,000,000USD107,900,000USD9,517,373,100USD101,900,000USD25,000USD
    Unclassified Non Current Assets——-102,300,000USD-108,600,000USD-107,900,000USD-9,517,373,100USD-101,900,000USD—
    Current Deferred Revenue——————400,000USD-268,209,000USD
    SourceDisclosureDeterministicFinalLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacy

    Balance sheet Yearly

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricFY 20252025-12-31 · USDFY 20242024-12-31 · USDFY 20232023-12-31 · USDFY 20222022-12-31 · USDFY 20212021-12-31 · USDFY 20202020-12-31 · USDFY 20192019-12-31 · USDFY 20182018-12-31 · USD
    Total Assets10,576,500,000USD9,364,100,000USD12,299,100,000USD13,501,666,000USD17,799,393,000USD12,972,618,000USD8,008,859,000USD5,611,068,000USD
    Intangible Assets174,300,000USD293,600,000USD320,500,000USD332,100,000USD253,900,000USD199,500,000USD145,500,000USD133,100,000USD
    Other Current Assets150,300,000USD153,300,000USD171,700,000USD153,343,000USD124,785,000USD107,040,000USD118,831,000USD202,424,000USD
    Total Liab3,122,900,000USD2,794,800,000USD3,557,900,000USD3,886,414,000USD4,114,157,000USD3,092,678,000USD2,253,802,000USD1,590,737,000USD
    Total Stockholder Equity7,453,600,000USD6,569,300,000USD8,741,200,000USD9,615,252,000USD13,685,236,000USD9,879,940,000USD5,755,057,000USD4,020,331,000USD
    Other Current Liab313,500,000USD271,400,000USD301,500,000USD312,227,000USD404,922,000USD353,975,000USD266,896,000USD244,728,000USD
    Common Stock3,010USD3,030USD3,000USD3,000USD3,000USD3,000USD3,000USD3,000USD
    Capital Stock0USD0USD3,000USD3,000USD3,000USD3,000USD3,000USD3,000USD
    Retained Earnings8,176,300,000USD7,416,400,000USD9,260,600,000USD9,898,203,000USD13,525,343,000USD9,268,012,000USD5,470,779,000USD3,722,073,000USD
    Good Will579,800,000USD410,500,000USD413,600,000USD406,500,000USD347,300,000USD291,900,000USD264,100,000USD219,800,000USD
    Other Assets102,700,000USD2,511,800,000USD94,850,000USD47,000USD82,000USD13,000USD56,000USD-7,000USD
    Cash531,799,999USD488,100,000USD403,800,000USD434,215,000USD470,783,000USD662,205,000USD660,672,000USD431,526,000USD
    Cash And Equivalents529,800,000USD488,100,000USD403,815,000USD434,215,000USD470,783,000USD662,205,000USD660,672,000USD431,526,000USD
    Cash And Short Term Investments1,542,700,000USD1,664,500,000USD1,607,100,000USD1,790,672,000USD869,918,000USD991,118,000USD1,114,645,000USD844,796,000USD
    Total Current Assets2,906,200,000USD3,030,300,000USD3,048,300,000USD3,157,976,000USD1,990,479,000USD2,139,835,000USD2,180,155,000USD2,023,478,000USD
    Total Current Liabilities517,000,000USD467,800,000USD522,800,000USD568,708,000USD680,938,000USD631,536,000USD905,495,000USD450,795,000USD
    Net Debt999,200,000USD886,600,000USD1,001,700,000USD953,883,000USD-247,407,000USD-436,470,000USD-9,489,000USD7,904,000USD
    Short Term Debt37,900,000USD42,900,000USD40,900,000USD36,801,000USD36,924,000USD38,307,000USD461,565,000USD493,000USD
    Short Long Term Debt1,300,000USD1,200,000USD486,000USD465,000USD489,000USD1,798,000USD426,172,000USD493,000USD
    Short Long Term Debt Total1,531,000,000USD1,374,700,000USD1,405,500,000USD1,388,098,000USD223,376,000USD225,735,000USD651,183,000USD439,430,000USD
    Long Term Debt1,203,000,000USD1,200,400,000USD1,199,052,000USD1,197,716,000USD10,514,000USD12,258,000USD13,579,000USD438,937,000USD
    Long Term Investments6,103,600,000USD4,839,200,000USD7,698,070,000USD8,830,892,000USD14,387,006,000USD9,561,140,000USD4,638,205,000USD2,655,709,000USD
    Short Term Investments1,010,900,000USD1,176,400,000USD1,203,300,000USD1,356,457,000USD399,135,000USD328,913,000USD453,973,000USD413,270,000USD
    Net Receivables472,500,000USD452,500,000USD489,000,000USD494,645,000USD423,537,000USD419,424,000USD392,672,000USD392,443,000USD
    Inventory740,700,000USD760,000,000USD780,500,000USD719,316,000USD572,239,000USD622,253,000USD554,007,000USD583,815,000USD
    Accounts Payable129,000,000USD122,300,000USD144,600,000USD135,041,000USD141,941,000USD139,451,000USD107,014,000USD122,450,000USD
    Property Plant Equipment Net709,900,000USD688,600,000USD723,700,000USD679,552,000USD716,437,000USD693,507,000USD701,207,000USD508,690,000USD
    Property Plant Equipment Gross1,970,900,000USD1,797,800,000USD1,790,430,000USD1,508,020,000USD1,488,568,000USD1,452,761,000USD701,207,000USD508,690,000USD
    Accumulated Other Comprehensive Income-189,100,000USD-538,200,000USD-336,000,000USD-466,822,000USD-175,553,000USD282,456,000USD-87,348,000USD-46,958,000USD
    Common Stock Shares Outstanding27,281,000shares28,214,000shares29,209,000shares29,785,000shares30,208,000shares30,160,000shares30,184,000shares30,228,000shares
    Non Current Assets Total7,670,300,000USD6,333,800,000USD9,250,800,000USD10,343,643,000USD15,808,832,000USD10,832,770,000USD5,828,648,000USD3,587,597,000USD
    Non Current Liabilities Total2,605,900,000USD2,327,000,000USD3,035,100,000USD3,317,706,000USD3,433,219,000USD2,461,142,000USD1,348,307,000USD1,139,942,000USD
    Non Current Liabilities Other197,800,000USD177,200,000USD195,113,000USD349,509,000USD358,129,000USD372,099,000USD336,941,000USD147,766,000USD
    Non Currrent Assets Other102,300,000USD101,900,000USD94,900,000USD94,599,000USD104,189,000USD86,723,000USD79,636,000USD70,298,000USD
    Net Working Capital2,389,200,000USD2,562,500,000USD2,525,531,000USD2,589,268,000USD1,308,150,000USD1,508,299,000USD1,274,660,000USD1,572,683,000USD
    Unclassified Non Current Assets-102,300,000USD-2,511,800,000USD-94,820,000USD—————
    Unclassified Current Liabilities35,300,000USD30,000,000USD-35,723,686,000USD31,963,000USD45,810,000USD55,537,000USD-389,887,000USD55,695,000USD
    Unclassified Non Current Liabilities1,205,100,000USD949,400,000USD1,640,935,000USD-1,966,393,000USD-3,411,713,000USD-2,448,884,000USD-1,158,710,000USD-701,005,000USD
    Unclassified Equity-533,603,010USD-308,903,030USD-183,406,000USD447,451,000USD441,730,000USD429,373,000USD410,017,000USD394,339,000USD
    Current Deferred Revenue——35,759,000,000USD52,211,000USD50,852,000USD42,468,000USD33,735,000USD26,936,000USD
    Deferred Long Term Liab———1,770,481,000USD3,059,080,000USD2,076,785,000USD997,787,000USD553,239,000USD
    Other Liab———1,966,393,000USD3,417,209,000USD2,448,884,000USD1,158,710,000USD701,005,000USD
    Accumulated Depreciation———-1,009,408,000USD-997,616,000USD-961,390,000USD-882,833,000USD-818,139,000USD
    Treasury Stock———-263,586,000USD-106,290,000USD-99,907,000USD-38,397,000USD-49,129,000USD
    Net Tangible Assets———9,208,764,000USD13,065,852,000USD9,879,940,000USD5,755,057,000USD4,020,331,000USD
    SourceLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacy

    Cash flow YTD

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricQ2 20262026-06-30 · USD
    Stock Based Compensation29,500,000USD
    Change To Account Receivables13,200,000USD
    Change To Inventory-37,700,000USD
    Change To Liabilities6,600,000USD
    Change In Working Capital13,200,000USD
    Operating Cash Flow206,800,000USD
    Capital Expenditures-62,000,000USD
    Net Investments-99,000,000USD
    Unclassified Investing Cash Flow1,100,000USD
    Investing Cash Flow-159,900,000USD
    Net Debt Issuance-500,000USD
    Net Common Stock Issuance-79,400,000USD
    Unclassified Financing Cash Flow8,300,000USD
    Financing Cash Flow-71,600,000USD
    Effect Of Forex Changes On Cash11,300,000USD
    Change In Cash-13,400,000USD
    End Cash Flow518,800,000USD
    SourceDisclosureDeterministicFinal

    Cash flow Quarterly

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricQ4 20252025-12-31 · USDQ3 20252025-09-30 · USDQ1 20252025-03-31 · USDQ4 20242024-12-31 · USDQ3 20242024-09-30 · USDQ2 20242024-06-30 · USDQ1 20242024-03-31 · USDQ4 20232023-12-31 · USD
    Net Income720,000,000USD-341,900,000USD64,000,000USD-715,800,000USD653,200,000USD-2,165,500,000USD383,900,000USD349,700,000USD
    Depreciation52,400,000USD54,200,000USD38,100,000USD49,300,000USD38,900,000USD36,400,000USD37,100,000USD37,200,000USD
    Stock Based Compensation15,900,000USD14,900,000USD15,300,000USD16,400,000USD15,600,000USD15,000,000USD15,300,000USD16,200,000USD
    Other Non Cash Items-1,058,400,000USD511,400,000USD-31,100,000USD717,298,000USD-764,790,000USD2,891,246,000USD-420,508,000USD-313,853,000USD
    Change To Account Receivables3,900,000USD4,200,000USD37,200,000USD-9,400,000USD-7,400,000USD-4,400,000USD37,400,000USD-20,200,000USD
    Change To Inventory51,600,000USD13,600,000USD-17,900,000USD24,500,000USD15,200,000USD-22,400,000USD-8,800,000USD15,400,000USD
    Change In Working Capital260,700,000USD-14,400,000USD43,600,000USD56,954,000USD220,700,000USD-679,500,000USD54,000,000USD-8,200,000USD
    Total Cash From Operating Activities164,900,000USD120,900,000USD129,900,000USD124,152,000USD163,610,000USD97,646,000USD69,792,000USD81,047,000USD
    Capital Expenditures-45,800,000USD-31,700,000USD-34,400,000USD-42,904,000USD-63,639,000USD-42,281,000USD-40,176,000USD-42,245,000USD
    Free Cash Flow119,100,000USD89,200,000USD95,500,000USD81,248,000USD99,971,000USD55,365,000USD29,616,000USD38,802,000USD
    Investments11,600,000USD-43,000,000USD2,900,000USD-30,544,000USD-55,636,000USD-30,927,000USD-43,093,000USD72,197,000USD
    Total Cashflows From Investing Activities-34,200,000USD-43,000,000USD2,900,000USD-30,544,000USD-55,636,000USD-30,927,000USD-43,093,000USD72,197,000USD
    Net Borrowings-200,000USD0USD-100,000USD-41,000USD-100,000USD———
    Total Cash From Financing Activities3,300,000USD-52,500,000USD-97,700,000USD-26,248,000USD-95,986,000USD-96,587,000USD21,000USD-200,620,000USD
    Sale Purchase Of Stock-279,700,000USD-53,400,000USD-101,900,000USD-14,000USD-97,837,000USD-101,000,000USD-4,749,000USD-200,000,000USD
    Change In Cash131,999,999USD26,500,000USD33,300,000USD77,612,000USD4,473,000USD-26,037,000USD29,383,000USD-53,946,000USD
    Begin Period Cash Flow397,800,000USD371,700,000USD489,800,000USD412,188,000USD407,715,000USD433,752,000USD404,369,000USD458,315,000USD
    End Period Cash Flow529,799,999USD398,200,000USD523,100,000USD489,800,000USD412,188,000USD407,715,000USD433,752,000USD404,369,000USD
    Other Cashflows From Investing Activities793,600,000USD-1,800,000USD190,509,300USD-39,000USD-23,353,000USD66,000USD26,000USD107,000USD
    Other Cashflows From Financing Activities-400,000USD-2,200,000USD4,300,000USD-26,193,000USD1,974,000USD4,531,000USD4,888,000USD-502,000USD
    Unclassified Operating Cash Flow174,300,000USD-103,300,000USD——————
    Unclassified Investing Cash Flow-793,600,000USD33,500,000USD-156,109,300USD42,943,000USD86,992,000USD42,215,000USD40,150,000USD42,138,000USD
    Unclassified Financing Cash Flow283,600,000USD65,800,000USD——15,812,000USD—15,717,000USD85,438,882,000USD
    Dividends Paid—-62,700,000USD——-15,835,000USD—-15,835,000USD-85,439,000,000USD
    SourceLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacy

    Cash flow Yearly

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricFY 20252025-12-31 · USDFY 20242024-12-31 · USDFY 20232023-12-31 · USDFY 20222022-12-31 · USDFY 20212021-12-31 · USDFY 20202020-12-31 · USDFY 20192019-12-31 · USDFY 20142014-12-31 · USD
    Net Income759,900,000USD-1,844,200,000USD-637,300,000USD-3,627,535,000USD4,245,902,000USD3,814,200,000USD1,758,675,000USD88,800,000USD
    Depreciation205,400,000USD151,600,000USD145,900,000USD137,296,000USD133,801,000USD138,600,000USD134,238,000USD149,900,000USD
    Stock Based Compensation58,000,000USD62,300,000USD61,300,000USD60,900,000USD51,200,000USD41,600,000USD35,600,000USD14,900,000USD
    Other Non Cash Items-879,200,000USD2,706,300,000USD1,237,843,000USD5,272,424,000USD-3,737,114,000USD-4,498,328,000USD-1,490,408,000USD2,012,000USD
    Change To Account Receivables19,600,000USD16,200,000USD11,400,000USD-87,400,000USD-20,400,000USD-15,000,000USD1,600,000USD11,100,000USD
    Change To Inventory68,900,000USD8,500,000USD-46,300,000USD-158,800,000USD46,100,000USD-52,100,000USD24,200,000USD5,800,000USD
    Change In Working Capital275,600,000USD-620,800,000USD-432,800,000USD-407,038,000USD13,932,000USD1,088,900,000USD55,392,000USD17,700,000USD
    Total Cash From Operating Activities532,200,000USD455,200,000USD374,943,000USD194,447,000USD656,521,000USD584,972,000USD457,897,000USD273,312,000USD
    Capital Expenditures-157,600,000USD-189,000,000USD-156,680,000USD-114,157,000USD-120,803,000USD-108,564,000USD-98,532,000USD-136,478,000USD
    Free Cash Flow374,600,000USD266,200,000USD218,263,000USD80,290,000USD535,718,000USD476,408,000USD359,365,000USD136,834,000USD
    Investments186,300,000USD-160,200,000USD-110,541,000USD-994,211,000USD-538,171,000USD119,601,000USD-119,304,000USD-9,631,000USD
    Total Cashflows From Investing Activities-189,700,000USD-160,200,000USD20,208,000USD-1,207,593,000USD-784,438,000USD-69,894,000USD-208,889,000USD-190,511,000USD
    Net Borrowings-500,000USD-400,000USD-500,000USD1,185,710,000USD-3,020,000USD-426,938,000USD-1,129,000USD-2,337,000USD
    Total Cash From Financing Activities-283,200,000USD-218,800,000USD-425,647,000USD973,576,000USD-55,429,000USD-523,041,000USD-22,758,000USD11,689,000USD
    Sale Purchase Of Stock-295,500,000USD-203,600,000USD-428,728,000USD-215,679,000USD-49,998,000USD-100,004,000USD-28,000,000USD15,051,000USD
    Change In Cash40,299,999USD85,400,000USD-30,175,000USD-36,589,000USD-195,982,000USD4,464,000USD228,487,000USD81,700,000USD
    Begin Period Cash Flow489,800,000USD404,400,000USD434,544,000USD471,133,000USD667,115,000USD662,651,000USD434,164,000USD331,551,000USD
    End Period Cash Flow532,200,000USD489,800,000USD404,369,000USD434,544,000USD471,133,000USD667,115,000USD662,651,000USD413,251,000USD
    Other Cashflows From Investing Activities793,600,000USD-23,300,000USD211,000USD-100,600,000USD-658,922,000USD3,484,000USD129,000USD225,000USD
    Other Cashflows From Financing Activities-3,000,000USD-14,800,000USD3,548,000USD-212,134,000USD-2,411,000USD3,901,000USD5,885,000USD-1,549,000USD
    Unclassified Operating Cash Flow112,500,000USD——-1,241,600,000USD-51,200,000USD—-35,600,000USD—
    Unclassified Investing Cash Flow-1,012,000,000USD212,300,000USD287,218,000USD—533,458,000USD-84,415,000USD8,818,000USD-44,627,000USD
    Unclassified Financing Cash Flow15,800,000USD—100,101,033,000USD68,399,679,000USD35,282,000,000USD20,198,000USD3,831,486,000USD—
    Dividends Paid——-100,101,000,000USD-68,184,000,000USD-35,282,000,000USD-20,198,000USD-3,831,000,000USD0USD
    Change To Liabilities———-1,335,800,000USD1,152,200,000USD1,103,600,000USD460,800,000USD-16,200,000USD
    Cash And Cash Equivalents Changes———-39,570,000USD-195,982,000USD4,464,000USD228,487,000USD81,700,000USD
    Exchange Rate Changes————-12,636,000USD12,427,000USD2,237,000USD-12,790,000USD
    SourceLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacy

    Operating metrics

    No operating metrics are currently published for this company.

    Revenue breakdown

    PeriodDimensionBusiness / regionRevenueCurrencySource
    Q2 2026Quarterly · 2026-06-30GeographyAmericas44,500,000USDDisclosure
    Q2 2026Quarterly · 2026-06-30GeographyAsia Pacific121,800,000USDDisclosure
    Q2 2026Quarterly · 2026-06-30GeographyEurope229,200,000USDDisclosure
    Q2 2026Quarterly · 2026-06-30GeographyUnited States255,500,000USDDisclosure
    Q2 2026Quarterly · 2026-06-30SegmentClinical Diagnostics399,000,000USDDisclosure
    Q2 2026Quarterly · 2026-06-30SegmentLife Science252,000,000USDDisclosure
    Q1 2026Quarterly · 2026-03-31GeographyAmericas45,100,000USD0000012208-26-000035
    Q1 2026Quarterly · 2026-03-31GeographyAsia Pacific110,400,000USD0000012208-26-000035
    Q1 2026Quarterly · 2026-03-31GeographyEurope206,800,000USD0000012208-26-000035
    Q1 2026Quarterly · 2026-03-31GeographyUnited States229,800,000USD0000012208-26-000035
    Q1 2026Quarterly · 2026-03-31SegmentClinical Diagnostics363,600,000USD0000012208-26-000035
    Q1 2026Quarterly · 2026-03-31SegmentLife Science228,500,000USD0000012208-26-000035
    Q4 2025Quarterly · 2025-12-31GeographyAmericas44,700,000USDLegacy provider
    Q4 2025Quarterly · 2025-12-31GeographyAsia Pacific161,800,000USDLegacy provider
    Q4 2025Quarterly · 2025-12-31GeographyEurope242,600,000USDLegacy provider
    Q4 2025Quarterly · 2025-12-31GeographyUnited States244,100,000USDLegacy provider
    Q4 2025Quarterly · 2025-12-31SegmentAll Other Segments0USDLegacy provider
    Q4 2025Quarterly · 2025-12-31SegmentClinical Diagnostics425,300,000USDLegacy provider
    Q4 2025Quarterly · 2025-12-31SegmentLife Science267,900,000USDLegacy provider
    FY 2025Yearly · 2025-12-31GeographyAmericas165,400,000USD0000012208-26-000010
    FY 2025Yearly · 2025-12-31GeographyAsia Pacific513,300,000USD0000012208-26-000010
    FY 2025Yearly · 2025-12-31GeographyEurope881,800,000USD0000012208-26-000010
    FY 2025Yearly · 2025-12-31GeographyUnited States1,022,700,000USD0000012208-26-000010
    FY 2025Yearly · 2025-12-31SegmentAll Other Segments0USD0000012208-26-000010
    FY 2025Yearly · 2025-12-31SegmentClinical Diagnostics1,562,100,000USD0000012208-26-000010
    FY 2025Yearly · 2025-12-31SegmentLife Science1,021,100,000USD0000012208-26-000010
    Q3 2025Quarterly · 2025-09-30GeographyAmericas39,800,000USD0000012208-25-000077
    Q3 2025Quarterly · 2025-09-30GeographyAsia Pacific121,000,000USD0000012208-25-000077
    Q3 2025Quarterly · 2025-09-30GeographyEurope222,200,000USD0000012208-25-000077
    Q3 2025Quarterly · 2025-09-30GeographyUnited States270,000,000USD0000012208-25-000077
    Q3 2025Quarterly · 2025-09-30SegmentAll Other Segments0USD0000012208-25-000077
    Q3 2025Quarterly · 2025-09-30SegmentClinical Diagnostics391,200,000USD0000012208-25-000077
    Q3 2025Quarterly · 2025-09-30SegmentLife Science261,800,000USD0000012208-25-000077
    Q2 2025Quarterly · 2025-06-30GeographyAmericas41,100,000USD0000012208-25-000052
    Q2 2025Quarterly · 2025-06-30GeographyAsia Pacific126,400,000USD0000012208-25-000052
    Q2 2025Quarterly · 2025-06-30GeographyEurope217,200,000USD0000012208-25-000052
    Q2 2025Quarterly · 2025-06-30GeographyUnited States266,900,000USD0000012208-25-000052
    Q2 2025Quarterly · 2025-06-30SegmentAll Other Segments0USD0000012208-25-000052
    Q2 2025Quarterly · 2025-06-30SegmentClinical Diagnostics388,800,000USD0000012208-25-000052
    Q2 2025Quarterly · 2025-06-30SegmentLife Science262,800,000USD0000012208-25-000052
    Q1 2025Quarterly · 2025-03-31GeographyAmericas39,800,000USD0000012208-26-000035
    Q1 2025Quarterly · 2025-03-31GeographyAsia Pacific104,100,000USD0000012208-26-000035
    Q1 2025Quarterly · 2025-03-31GeographyEurope199,800,000USD0000012208-26-000035
    Q1 2025Quarterly · 2025-03-31GeographyUnited States241,700,000USD0000012208-26-000035
    Q1 2025Quarterly · 2025-03-31SegmentAll Other Segments0USD0000012208-25-000026
    Q1 2025Quarterly · 2025-03-31SegmentClinical Diagnostics356,800,000USD0000012208-25-000026
    Q1 2025Quarterly · 2025-03-31SegmentLife Science228,600,000USD0000012208-25-000026
    Q4 2024Quarterly · 2024-12-31GeographyAmericas41,300,000USDLegacy provider
    Q4 2024Quarterly · 2024-12-31GeographyAsia Pacific146,300,000USDLegacy provider
    Q4 2024Quarterly · 2024-12-31GeographyEurope221,700,000USDLegacy provider
    Q4 2024Quarterly · 2024-12-31GeographyUnited States258,200,000USDLegacy provider
    Q4 2024Quarterly · 2024-12-31SegmentAll Other Segments0USDLegacy provider
    Q4 2024Quarterly · 2024-12-31SegmentClinical Diagnostics392,500,000USDLegacy provider
    Q4 2024Quarterly · 2024-12-31SegmentLife Science275,000,000USDLegacy provider
    FY 2024Yearly · 2024-12-31GeographyAmericas169,300,000USD0000012208-26-000010
    FY 2024Yearly · 2024-12-31GeographyAsia Pacific521,600,000USD0000012208-26-000010
    FY 2024Yearly · 2024-12-31GeographyEurope834,100,000USD0000012208-26-000010
    FY 2024Yearly · 2024-12-31GeographyUnited States1,041,500,000USD0000012208-26-000010
    FY 2024Yearly · 2024-12-31SegmentAll Other Segments500,000USD0000012208-26-000010
    FY 2024Yearly · 2024-12-31SegmentClinical Diagnostics1,537,900,000USD0000012208-26-000010
    FY 2024Yearly · 2024-12-31SegmentLife Science1,028,100,000USD0000012208-26-000010
    Q3 2024Quarterly · 2024-09-30GeographyAmericas40,900,000USD0000012208-25-000077
    Q3 2024Quarterly · 2024-09-30GeographyAsia Pacific126,900,000USD0000012208-25-000077
    Q3 2024Quarterly · 2024-09-30GeographyEurope205,700,000USD0000012208-25-000077
    Q3 2024Quarterly · 2024-09-30GeographyUnited States276,200,000USD0000012208-25-000077
    Q3 2024Quarterly · 2024-09-30SegmentAll Other Segments0USD0000012208-25-000077
    Q3 2024Quarterly · 2024-09-30SegmentClinical Diagnostics388,800,000USD0000012208-25-000077
    Q3 2024Quarterly · 2024-09-30SegmentLife Science260,900,000USD0000012208-25-000077
    FY 2023Yearly · 2023-12-31GeographyAmericas166,500,000USD0000012208-26-000010
    FY 2023Yearly · 2023-12-31GeographyAsia Pacific563,000,000USD0000012208-26-000010
    FY 2023Yearly · 2023-12-31GeographyEurope819,800,000USD0000012208-26-000010
    FY 2023Yearly · 2023-12-31GeographyUnited States1,121,900,000USD0000012208-26-000010
    FY 2023Yearly · 2023-12-31SegmentAll Other Segments3,500,000USD0000012208-26-000010
    FY 2023Yearly · 2023-12-31SegmentClinical Diagnostics1,489,300,000USD0000012208-26-000010
    FY 2023Yearly · 2023-12-31SegmentLife Science1,178,400,000USD0000012208-26-000010
    FY 2022Yearly · 2022-12-31GeographyAmericas155,400,000USD0000012208-25-000007
    FY 2022Yearly · 2022-12-31GeographyAsia Pacific639,400,000USD0000012208-25-000007
    FY 2022Yearly · 2022-12-31GeographyEurope851,900,000USD0000012208-25-000007
    FY 2022Yearly · 2022-12-31GeographyUnited States1,155,500,000USD0000012208-25-000007
    FY 2022Yearly · 2022-12-31SegmentAll Other Segments4,000,000USD0000012208-25-000007
    FY 2022Yearly · 2022-12-31SegmentClinical Diagnostics1,451,000,000USD0000012208-25-000007
    FY 2022Yearly · 2022-12-31SegmentLife Science1,347,200,000USD0000012208-25-000007
    FY 2021Yearly · 2021-12-31GeographyAmericas156,600,000USD0000012208-24-000013
    FY 2021Yearly · 2021-12-31GeographyAsia Pacific688,400,000USD0000012208-24-000013
    FY 2021Yearly · 2021-12-31GeographyEurope946,900,000USD0000012208-24-000013
    FY 2021Yearly · 2021-12-31GeographyUnited States1,130,600,000USD0000012208-24-000013
    FY 2021Yearly · 2021-12-31SegmentAll Other Segments5,800,000USD0000012208-24-000013
    FY 2021Yearly · 2021-12-31SegmentClinical Diagnostics1,515,900,000USD0000012208-24-000013
    FY 2021Yearly · 2021-12-31SegmentLife Science1,400,800,000USD0000012208-24-000013
    FY 2020Yearly · 2020-12-31GeographyAmericas136,600,000USD0000012208-23-000031
    FY 2020Yearly · 2020-12-31GeographyAsia Pacific546,500,000USD0000012208-23-000031
    FY 2020Yearly · 2020-12-31GeographyEurope857,700,000USD0000012208-23-000031
    FY 2020Yearly · 2020-12-31GeographyUnited States1,004,800,000USD0000012208-23-000031
    FY 2020Yearly · 2020-12-31SegmentAll Other Segments8,600,000USD0000012208-23-000031
    FY 2020Yearly · 2020-12-31SegmentClinical Diagnostics1,305,200,000USD0000012208-23-000031
    FY 2020Yearly · 2020-12-31SegmentLife Science1,231,800,000USD0000012208-23-000031
    FY 2019Yearly · 2019-12-31GeographyAmericas137,300,000USD0000012208-22-000011
    FY 2019Yearly · 2019-12-31GeographyAsia Pacific505,000,000USD0000012208-22-000011
    FY 2019Yearly · 2019-12-31GeographyEurope770,300,000USD0000012208-22-000011
    FY 2019Yearly · 2019-12-31GeographyUnited States899,100,000USD0000012208-22-000011

    Periods follow company fiscal calendars. Quarterly, annual and year-to-date amounts are shown separately. Missing values are not zero. Data may be delayed, incomplete or corrected; follow the disclosure links to verify figures.